Press release


21/01/2018
Lipopharma awarded a 6,15M€ grant by the H2020 Programme to conduct a PIIb trial with 2OHOA in patients with newly-diagnosed glioblastoma
The European Commission (EC) has awarded a 6,15M€ grant to develop the project CLINGLIO to a multinational consortium lead by Lipopharma and integrated by 12 leading clinical research institutions, Universities and SMEs from Europe, Israel and the USA. The objective of CLINGLIO is the execution of “A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma”. The duration of the CLINGLIO project is 36 months and the starting date is 1st of December, 2017
 
Palma de Mallorca (Spain) and Acton (MA, USA). January 21st 2018.– Lipopharma, a pioneering clinical stage biopharmaceutical company developing a new generation of products modulating metabolism of membrane lipids based on the groundbreaking MLT platform, announces that the European Commission has awarded a 6,15M€ grant to the CLINGLIO consortium, lead by Lipopharma, to execute the project entitled “A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma”.

 
 
Related links:
 
 
Permalink  
 
Developed by Web4Bio